RANI Director Michelle Gilson Receives 247,200-Share Option Award

What Happened
Michelle Gilson, a director of Rani Therapeutics Holdings, Inc. (RANI), was granted a derivative award covering 247,200 shares on August 3, 2026. The Form 4 reports the acquisition price as $0.00 because this is an equity award/option grant (not an open-market purchase); the filing does not provide an exercise/strike price or an immediate cash value.

Key Details

• Transaction date: 2026-08-03. Form 4 filed: 2026-08-04 (appears timely).
• Transaction type: Award/Grant (Insider transaction code A) — derivative security (option).
• Shares/options granted: 247,200.
• Shares owned after transaction: not specified in the filing.
• Vesting (per footnote): 1/3 of the shares vest on the first anniversary, then 1/36 of the shares vest monthly thereafter; fully vested on the third anniversary or immediately upon a Change in Control, subject to continuous service.
• No immediate exercise or sale reported; this is a compensation grant, not a market purchase or sale.

Context
This is a typical director compensation award intended to align long-term interests with shareholders and to retain the director; it does not represent an immediate purchase or sale of shares. The eventual benefit to the insider depends on the option’s strike price and RANI’s future stock price when (and if) the options are exercised.